Kyverna Therapeutics, Inc.KYTXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank18
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P18
Within normal range
vs 2Y Ago
-32.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q3 2025-35.59%
Q2 202528.87%
Q1 2025-21.19%
Q4 2024-34.82%
Q3 2024-13.71%
Q2 20245.29%
Q1 2024-37.50%
Q4 2023-66.75%
Q3 20231.11%
Q2 20231.75%
Q1 2023-29.95%
Q4 20220.00%